Open access
Open access
Powered by Google Translator Translator

Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

12 May, 2021 | 08:42h | UTC

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline – The BMJ

Editorial: Newer drug treatments for type 2 diabetes

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.